Lung Cancer

breathcrumb

Lung Cancer

Breast Cancer Biomarkers

Increasing levels


  • Agalactosyl biantennary glycans G0F and glycans containing sLex epitope A3F1G1 and A2F1G1.
  • Highly sialylated antenna fucosylated glycans1.
  • Fucosylated and sialylated glycans
  • High-mannose type structures.
  • Fucosylated glycans.
  • Glycan Standard 13C Biantennary A1(3)(Sial α-2,3)
  • Glycan Standard <sup>13</sup>C Tetraantennary A4-G1a
  • Bis α-2,6-sialylated biantennary glycopeptide from egg yolk
  • Bis α-2,3-sialylated, galactosylated biantennary glycopeptide

Breast Cancer Biomarkers

Decreasing levels


  • Decreased leveles of sialylated glycans.
  • Bis α-2,3-sialylated, galactosylated biantennary glycopeptide

References:
[1] R. Saldova, et al., Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts, Ann. Oncol. 22 (2011) 1113–1119.

[2] U.M. Abd Hamid, et al., A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression, Glycobiology 18 (2008) 1105

[3] Z. Kyselova, et al., Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles, Clin. Chem. 54 (2008) 1166–1175.

[4] A. Pierce, et al., Levels of specific glycans significantly distinguish lymph node–

[5] de Leoz, M. L., et al., (2011) High-mannose glycans are elevated during breast cancer progression. Mol. Cell. Proteomics 10, M110.00271

[6] Alley, W. R., Jr., et al., (2010) Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancerbiomarker discovery. Anal. Chem. 82, 5095–5106